




EMLc
Codes ATC: L01XA02

Indication	Retinoblastoma <span>Code ICD11: 2D52.2</span>
INN	Carboplatin
Type de médicament	Chemical agent
Type de liste	Liste complémentaire (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL
Historique des statuts LME	Ajouté pour la première fois en 2009 (TRS 958) Modifié en 2015 (TRS 994)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets.</a> 
Balises	<span>Cancer</span>
Wikipédia	<a href="#">Carboplatin</a> 
DrugBank	<a href="#">Carboplatin</a> 

## Résumé des preuves et recommandation du comité d'experts

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for retinoblastoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of the treatment protocols for retinoblastoma is attached.

Rapport du comité d'experts 
